Zentalis Pharmaceuticals, Inc.

NASDAQ:ZNTL

Biotechnology

Healthcare
$1.36 +0.83%

+$0.03 today

Market cap
$133.64M
Beta
1.98
P/E (TTM)
-2.1
EPS (TTM)
-$1.77
52W Low $1.13High $6.95

Volume 1.21M

Average 2.00M

ZNTL Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Zentalis Pharmaceuticals, Inc.NASDAQ: ZNTL

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares dips below year-ago levels

Q1 FY2026 weighted avg shares of 70.26M shares fell 2.0% year over year, behind the +0.4% change in trailing-twelve-month weighted avg shares. Sequentially, it fell 2.0% from the prior quarter. Over 3 fiscal years it compounded at +10.8% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -2.0% toward the trailing-twelve-month pace of +0.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
70.26M-2.0% QoQ
Last fiscal yearDec 2025
71.87M+1.1% YoY
LTMMar 2026
71.52M+0.4% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-2.0%——
1 year+1.1%——
3-year CAGR+10.8%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
71.87M USD
Year-over-year change
+1.1%
4-year CAGR
+13.9%

Weighted Avg Shares vs competitors

How ZNTL compares with its peers on the latest reported figures

  • ZNTL's LTM Mar 2026 weighted avg shares of 71.52M shares is the 2nd highest of the 11 companies compared; the peer median is 44.26M shares.
  • Its year-over-year change of +0.4% is the 10th highest of 11, against a peer median of +2.8%.
  • Over three fiscal years its annual growth of +10.8% compares with a peer median of +15.7%.
ZNTL Competitors Peer median
Weighted Avg Shares for ZNTL and competitors
Company Period LTM YoY 3-year CAGR
STTKShattuck Labs, Inc.LTM Mar 202684.8M +66.7%+18.0%
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 202671.52M +0.4%+10.8%
WHWKWhitehawk Therapeutics IncLTM Mar 202668.95M +154.8%+40.1%
MGNXMacroGenics, Inc.LTM Mar 202663.24M +0.8%+0.9%
PLRXPliant Therapeutics, Inc.LTM Mar 202661.49M +1.3%+13.5%
ALXOALX Oncology Holdings Inc.LTM Mar 202653.9M +2.3%+9.7%
IMMXImmix Biopharma, Inc.LTM Mar 202634.62M +19.9%+33.4%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 202624.5M +1.8%+11.6%
DTILPrecision BioSciences, Inc.LTM Mar 202612.13M +61.6%+63.6%
TILInstil Bio, Inc.LTM Mar 20266.73M +3.3%+1.0%
STROSutro Biopharma, Inc.LTM Mar 20266.42M -22.0%+18.8%
Peer median (excluding ZNTL) 44.26M+2.8%+15.7%

Competitors are the stored peer set for ZNTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00067.43M0
Cost of Revenue00000
Gross Profit00067.43M0
Gross Margin———100.0%—
Research & Development175.6M172.73M235.16M167.77M107.3M
Selling, General & Admin40.94M54.55M59.4M87.12M37.72M
Operating Expenses216.54M227.29M299.51M258.62M152.81M
Depreciation & Amortization544K1.43M1.39M1.29M739K
EBITDA(207.2M)(233.58M)(247.6M)(186.17M)(144.27M)
EBITDA Margin———-276.1%—
Operating Income(216.54M)(227.29M)(299.51M)(191.19M)(152.81M)
Operating Margin———-283.6%—
Interest Income02.26K000
Interest Expense02.58M000
Other Income / Expenses50.15M(10.3M)6.6M25.5M16.19M
Income Before Tax(166.39M)(237.58M)(292.91M)(165.69M)(136.62M)
Pre-Tax Margin———-245.7%—
Income Tax Expense(297K)(469K)(601K)177K442K
Net Income(158.73M)(236.81M)(292.19M)(165.84M)(137.06M)
Net Margin———-246.0%—
EPS (Basic)(3.72)(4.48)(4.47)(2.33)(1.91)
EPS (Diluted)(3.72)(4.48)(4.47)(2.33)(1.91)
Weighted Avg Shares42.69M52.86M65.41M71.08M71.87M
Weighted Avg Shares (Diluted)42.69M52.86M65.41M71.08M71.87M

Zentalis Pharmaceuticals, Inc.

NASDAQ:ZNTL

Intrinsic Alpha fair value

Locked

Current Price

$1.36

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.